Cholesterol Biosynthesis, Regulation, Transport, and Clinical Pharmacology
Structural Features, Origin, and Biological Roles of Cholesterol
Historical Discovery and Physiological Occurrence:
- Cholesterol was first isolated from human gallstones in .
- It is an essential neutral lipid found in animal tissues that can be obtained from dietary sources (exogenous pathway) or synthesized de novo by cells (endogenous pathway).
- While virtually all nucleated cells have the genetic and biochemical capacity to produce cholesterol, the liver is the primary site of de novo cholesterol biosynthesis in mammals, with significant synthesis also occurring in the intestine, adrenal cortex, and gonads.
Carbon Backbone Origin:
- All carbon atoms of the cholesterol molecule are derived biosynthetically from a single two-carbon precursor: the acetyl group of acetyl coenzyme A (.

- Primary Physiological Functions:
- Modulation of Membrane Fluidity: Cholesterol inserts into the phospholipid bilayer of cellular membranes. Its fused, planar four-ring steroid nucleus intercalates among the fatty acyl chains of phospholipids, while its polar hydroxyl () group interacts with phospholipid polar headgroups. This structure broadens the phase transition temperature of membranes, maintaining fluidity and mechanical stability across changing physiological temperatures.
- Precursor for Essential Biomolecules: Cholesterol serves as the obligate biochemical starting material for three major classes of biologically vital compounds:
- Steroid hormones (glucocorticoids, mineralocorticoids, androgens, estrogens, and progestagens).
- Bile salts (such as glycocholate and taurocholate), which act as biological detergents in lipid emulsification.
- Vitamin D ( or cholecalciferol), which regulates systemic calcium and phosphate homeostasis.
Overview of the Three Biosynthetic Stages
- Cholesterol biosynthesis is an energetically demanding and highly orchestrated pathway consisting of three overarching stages occurring across different subcellular compartments:
- Stage 1 (Cytoplasm): Synthesis of the activated five-carbon isoprene building block, isopentenyl pyrophosphate (), from mevalonate via the condensation of three molecules of acetyl CoA.
- Stage 2 (Endoplasmic Reticulum): Stepwise condensation of six molecules of isopentenyl pyrophosphate to generate the linear -carbon triterpene intermediate, squalene.
- Stage 3 (Endoplasmic Reticulum): Concerted cyclization of squalene to form the four-ring intermediate lanosterol, followed by a multi-step enzymatic remodeling into the -carbon cholesterol molecule.
Stage 1: Biosynthesis of Mevalonate and Isopentenyl Pyrophosphate
- Synthesis of 3-Hydroxy-3-Methylglutaryl CoA (HMG-CoA):
- Two molecules of acetyl CoA condense in a reversible reaction catalyzed by acetoacetyl CoA thiolase to yield acetoacetyl CoA () and release one molecule of free coenzyme A ().
- Acetoacetyl CoA condenses with a third molecule of acetyl CoA and water () in an irreversible aldol condensation catalyzed by 3-hydroxy-3-methylglutaryl-CoA synthase (), yielding 3-hydroxy-3-methylglutaryl CoA (, a intermediate) and releasing free coenzyme A.

Compartmentalization of HMG-CoA Metabolism:
- Cytoplasm: HMG-CoA is synthesized by cytoplasmic HMG-CoA synthase and is committed entirely toward mevalonate production and cholesterol biosynthesis.
- Mitochondria: HMG-CoA is synthesized by mitochondrial HMG-CoA synthase and is cleaved by HMG-CoA lyase into acetoacetate and acetyl CoA during ketone body synthesis (ketogenesis).
Synthesis of Mevalonate by HMG-CoA Reductase (HMGR):
- HMG-CoA is reduced to mevalonate in an irreversible, four-electron reduction catalyzed by HMG-CoA reductase (), consuming two equivalents of NADPH:
This reduction is the committed, rate-limiting step of the entire cholesterol biosynthetic pathway.
- Molecular Architecture of HMG-CoA Reductase:
HMGR is an integral glycoprotein anchored in the endoplasmic reticulum () membrane.
It contains two distinct domains:
- A membrane-spanning anchor consisting of eight transmembrane helices, which houses a sterol-sensing domain () responsible for sensing intracellular cholesterol levels and interacting with regulatory partners such as Insig () proteins.
- A soluble cytosolic domain that extends into the cytoplasm and harbors the catalytic site responsible for the enzymatic reduction of HMG-CoA to mevalonate.
The catalytic portion functions as a homotetramer (PDB ID: 1DQ9), with active sites situated at monomer-monomer interfaces.


- Phosphorylation and Decarboxylation of Mevalonate to Isopentenyl Pyrophosphate:
- Mevalonate undergoes three successive ATP-dependent phosphorylation reactions followed by a decarboxylation to generate 3-isopentenyl pyrophosphate ():
- First Phosphorylation: Mevalonate kinase transfers a terminal phosphoryl group from ATP to the terminal hydroxyl group of mevalonate, producing 5-phosphomevalonate and ADP.
- Second Phosphorylation: Phosphomevalonate kinase transfers a second phosphoryl group from ATP to 5-phosphomevalonate, producing 5-pyrophosphomevalonate and ADP.
- Third Phosphorylation and Decarboxylation: Pyrophosphomevalonate decarboxylase (diphosphomevalonate decarboxylase) uses a third molecule of ATP to transiently phosphorylate the tertiary hydroxyl group at . The resulting unstable intermediate undergoes a concerted decarboxylation and dephosphorylation, releasing carbon dioxide (), inorganic phosphate (), ADP, and the activated five-carbon isoprenoid, 3-isopentenyl pyrophosphate (.
- Energetic Cost: Generating a single molecule of isopentenyl pyrophosphate requires molecules of ATP. Because a cholesterol molecule contains carbons assembled from six activated units, a total of ATP equivalents are consumed during this phase.

Stage 2: Squalene Synthesis via Isoprene Condensation
- Isomerization of Isopentenyl Pyrophosphate:
- Isopentenyl pyrophosphate contains a terminal carbon-carbon double bond (). To enable condensation, IPP must be reversibly isomerized into its allylic structural isomer, dimethylallyl pyrophosphate (.
- This reaction is catalyzed by isopentenyl pyrophosphate isomerase, establishing an equilibrium between IPP and DMAPP.

Sequential Condensation Reactions:
- Formation of Geranyl Pyrophosphate ():
- DMAPP ( allylic donor) undergoes a head-to-tail condensation with IPP ( homoallylic acceptor), catalyzed by geranyl pyrophosphate synthase (prenyltransferase).
- The reaction proceeds via the ionization of the pyrophosphate leaving group on DMAPP, generating an allylic carbocation that is attacked by the double bond of IPP, followed by proton elimination. Inorganic pyrophosphate () is released, forming geranyl pyrophosphate (, ).
- Formation of Farnesyl Pyrophosphate ():
- Geranyl pyrophosphate () condenses head-to-tail with a second molecule of IPP (), releasing another to yield the -carbon intermediate, farnesyl pyrophosphate (.
- Thermodynamic Driving Force: Every head-to-tail condensation releases inorganic pyrophosphate (), which is rapidly and irreversibly hydrolyzed by cellular pyrophosphatases into two orthophosphates (), driving the biosynthetic reactions strongly toward product formation.
Reductive Tail-to-Tail Condensation to Squalene ():
- Two molecules of farnesyl pyrophosphate () undergo a tail-to-tail reductive condensation catalyzed by squalene synthase, an intrinsic enzyme localized to the endoplasmic reticulum membrane.
- This reaction requires NADPH as a reducing agent and releases two molecules of pyrophosphate:
- The resulting product is squalene, an unbranched, symmetrical -carbon triterpene containing six isolated double bonds.

Stage 3: Cyclization of Squalene and Conversion into Cholesterol
- Activation via Epoxidation:
- Squalene is activated for ring closure by squalene monooxygenase (squalene epoxidase), an ER-bound mixed-function oxygenase that requires molecular oxygen () and NADPH.
- One oxygen atom from is introduced across the terminal double bond of squalene to form squalene epoxide (), while the other oxygen atom is reduced to water ():
- Concerted Cyclization to Lanosterol:
- Squalene epoxide binds to oxidosqualene:lanosterol cyclase (lanosterol synthase) in a defined, chair-boat-chair-boat conformation.
- Protonation of the epoxide oxygen initiates a concerted, cationic cascade of ring closures through four successive double bonds, generating the protosterol cation featuring the fused four-ring steroid nucleus (rings A, B, C, and D).
- A sequence of two stereospecific 1,2-hydride shifts and two 1,2-methyl shifts terminates with the loss of a proton () from , forming the tetracyclic sterol intermediate lanosterol ().

- Multi-Step Remodeling of Lanosterol to Cholesterol:
- Lanosterol is transformed into cholesterol () through a complex sequence of individual enzymatic steps occurring entirely within the endoplasmic reticulum membrane.
- Key Biochemical Modifications:
- Oxidative Decarboxylation: Removal of three methyl groups—two from the position and one from the position. These carbons are eliminated as one molecule of formic acid () and two molecules of carbon dioxide ().
- Double-Bond Isomerization: The double bond at position migrates to the position of the B ring.
- Side-Chain Reduction: The aliphatic double bond at position of the hydrocarbon tail is enzymatically reduced.

Multi-Level Regulation of HMG-CoA Reductase and Cholesterol Biosynthesis
- Cellular cholesterol homeostasis is controlled through four feedback mechanisms that regulate the rate-limiting enzyme, HMG-CoA reductase:
- Transcriptional Control:
- The rate of HMGR mRNA synthesis is governed by the sterol-sensing transcription factor known as Sterol Regulatory Element-Binding Protein (.
- SREBP is embedded in the ER membrane alongside SCAP (). When intracellular sterol levels are elevated, sterols bind to SCAP and Insig, locking the SREBP-SCAP complex into the ER membrane.
- When cholesterol levels drop, Insig dissociates from SCAP. SCAP escorts SREBP via COPII vesicles to the Golgi apparatus, where two proteases (Site-1 Protease and Site-2 Protease) release the DNA-binding bHLH transcription factor domain of SREBP. This fragment enters the nucleus and binds Sterol Regulatory Elements () in the promoter region of the HMGR gene, stimulating transcription.
- Elevated intracellular cholesterol prevents this cleavage cascade, reducing the rate of HMGR mRNA transcription.
- Translational Control:
- Translation of existing HMGR mRNA transcripts is selectively inhibited by nonsterol isoprenoid metabolites derived from mevalonate (such as farnesyl pyrophosphate) and by dietary cholesterol metabolites.
- Regulated Proteolytic Degradation:
- The membrane-spanning region of HMGR contains a sterol-sensing domain (.
- High levels of sterols (such as lanosterol and oxysterols) induce conformational changes in the transmembrane helices of HMGR, stimulating its binding to Insig proteins in the ER membrane.
- Insig recruits membrane-associated ubiquitin ligases, triggering the polyubiquitination of cytosolic lysine residues on HMGR.
- Polyubiquitinated HMGR is extracted from the membrane by the VCP/p97 AAA-ATPase complex and targeted to the cytoplasmic proteasome for complete degradation.
- Post-Translational Phosphorylation:
- HMGR is inactivated through reversible covalent phosphorylation of a specific serine residue by AMP-activated protein kinase (.
- AMPK acts as an intracellular energy sensor: when cellular ATP levels are depleted and AMP concentrations rise (), AMPK phosphorylates HMGR, halting cholesterol biosynthesis.
- When cellular energy levels are high, a protein phosphatase dephosphorylates and reactivates HMGR.
Important Biomolecules Derived from Cholesterol
- Steroid Hormones:
- Cholesterol is the sole chemical precursor for all vertebrate steroid hormones (, , and classes).
- Side-Chain Cleavage: Biosynthesis of all steroid classes begins in the mitochondria with the cleavage of the cholesterol hydrocarbon tail by the desmolase complex (CYP11A1 / P450scc), a cytochrome P450 monooxygenase.
- The reaction hydroxylates cholesterol at positions and to form , followed by the oxidative scission of the carbon-carbon bond between and .
- This step cleaves a six-carbon isocaproaldehyde fragment from the steroid core, producing pregnenolone ().

- Steroid Hormone Interconversions:
- Pregnenolone () isomerizes and oxidizes to form progesterone (), the primary progestagen involved in maintaining the uterine endometrium during pregnancy.
- Progesterone serves as the metabolic branch point for:
- Glucocorticoids (, e.g., Cortisol): Regulate gluconeogenesis, glucose homeostasis, and anti-inflammatory responses.
- Mineralocorticoids (, e.g., Aldosterone): Synthesized in the adrenal zona glomerulosa; act on the distal tubules of the kidneys to enhance sodium reabsorption, potassium excretion, and systemic blood pressure.
- Androgens (, e.g., Testosterone): Male sex hormones produced in testicular Leydig cells and adrenal glands; responsible for male secondary sexual characteristics and anabolism.
- Estrogens (, e.g., Estradiol): Female sex hormones produced through the aromatization of the androgenic A-ring catalyzed by cytochrome P450 aromatase, with concomitant oxidative loss of the angular methyl group at position .

- Vitamin D Biosynthesis:
- Vitamin D is synthesized via a photochemical-thermal reaction sequence starting from the cholesterol biosynthetic intermediate, 7-dehydrocholesterol, situated in the epidermal layers of the skin.
- Photolysis: Absorption of ultraviolet () radiation (wavelengths ) causes the non-enzymatic cleavage of the bond in the B-ring of 7-dehydrocholesterol, generating the intermediate previtamin .
- Thermal Isomerization: Previtamin undergoes spontaneous, non-enzymatic thermal isomerization to form vitamin (cholecalciferol).
- Activation in Liver and Kidneys:
- Vitamin is transported to the liver, where 25-hydroxylase hydroxylates the side chain to yield 25-hydroxycholecalciferol (calcidiol).
- Calcidiol is transported to the proximal tubules of the kidneys, where adds an active hydroxyl group to produce 1,25-dihydroxycholecalciferol (calcitriol).
- Physiological Role and Pathology: Calcitriol acts via nuclear vitamin D receptors to stimulate intestinal calcium and phosphate absorption and facilitate bone mineralization. Deficiency results in impaired calcification of newly formed bone matrix and epiphyseal cartilage, manifesting as rickets in children and osteomalacia in adults.

- Bile Salt Biosynthesis:
- Bile salts are water-soluble derivatives of cholesterol synthesized in hepatocytes.
- During synthesis, multiple hydroxyl groups are introduced in an -orientation on the steroid ring system (initiating with the rate-limiting reaction), the double bond at is reduced, and the hydrocarbon side chain is oxidatively shortened to a carboxylic acid.
- The terminal carboxyl group is activated with coenzyme A and conjugated via an amide bond to either glycine or taurine (a cysteine derivative), yielding glycocholate and taurocholate.
- Conjugation lowers the of the molecule, ensuring that bile salts exist in a fully deprotonated, ionized, amphipathic state at the pH of the intestinal lumen.
- Bile salts are concentrated and stored in the gallbladder before being secreted into the duodenum. There, they act as detergents that emulsify dietary triacylglycerols and lipids into mixed micelles, expanding the surface area accessible to pancreatic lipases.

Plasma Lipoproteins and Inter-Organ Transport Pathways
Structural Organization of Lipoprotein Particles:
- Because unesterified cholesterol, cholesteryl esters, and triacylglycerols are insoluble in aqueous blood plasma, they are transported as spherical macromolecular assemblies known as lipoproteins.
- Core: Hydrophobic, containing neutral lipids (triacylglycerols and cholesteryl esters).
- Shell: Amphipathic monolayer consisting of phospholipids and unesterified free cholesterol, oriented with their hydrophilic headgroups facing outward toward the aqueous bloodstream.
- Apolipoproteins: Protein components embedded on the outer surface that maintain particle structural integrity, act as enzyme cofactors, and serve as specific ligands for cellular surface receptors.
Classification and Characteristics of Lipoproteins:
- Plasma lipoproteins are classified according to their buoyant density (determined via ultracentrifugation). Density is inversely related to lipid content and directly related to protein content.

Chylomicrons:
- Density:
- Diameter:
- Apolipoproteins: Apo B-48, Apo C, Apo E
- Composition: Triacylglycerol (TAG), Cholesteryl ester (CE), Free cholesterol (C), Phospholipid (PL), Protein (P)
- Physiological Role: Transport exogenous (dietary) fat and cholesterol from the intestine to peripheral tissues and the liver.
Very Low-Density Lipoprotein (VLDL):
- Density:
- Diameter:
- Apolipoproteins: Apo B-100, Apo C, Apo E
- Composition: TAG, CE, C, PL, P
- Physiological Role: Transport endogenously synthesized triacylglycerols from the liver to peripheral tissues.
Intermediate-Density Lipoprotein (IDL):
- Density:
- Diameter:
- Apolipoproteins: Apo B-100, Apo E
- Composition: TAG, CE, C, PL, P
- Physiological Role: Transient catabolic product of VLDL; serves as the immediate precursor for LDL.
Low-Density Lipoprotein (LDL):
- Density:
- Diameter:
- Apolipoproteins: Apo B-100
- Composition: TAG, CE, C, PL, P
- Physiological Role: Primary blood transporter of cholesterol to peripheral tissues; clinically referred to as "bad cholesterol".
High-Density Lipoprotein (HDL):
Density:
Diameter:
Apolipoproteins: Apo A
Composition: TAG, CE, C, PL, P
Physiological Role: Mediates reverse cholesterol transport, picking up excess cholesterol from peripheral tissues and delivering it to the liver for excretion or bile salt conversion; clinically referred to as "good cholesterol".
Functions of Key Apolipoproteins and Enzymes:
Apolipoprotein B-48 (Apo B-48): Synthesized in enterocytes via post-transcriptional RNA editing of Apo B mRNA (which introduces a premature stop codon); stabilizes nascent chylomicrons.
Apolipoprotein B-100 (Apo B-100): Synthesized in hepatocytes as the full-length translation product; stabilizes VLDL, IDL, and LDL, and serves as the recognition ligand for the LDL receptor.
Apolipoprotein C-II (Apo C-II): Transferred from circulating HDL to nascent chylomicrons and VLDL; acts as an obligate allosteric cofactor that activates lipoprotein lipase.
Apolipoprotein E (Apo E): Serves as a high-affinity recognition ligand that binds to LDL receptors and remnant receptors (LRP) on hepatocytes, facilitating endocytosis of chylomicron remnants and IDL.
Lipoprotein Lipase (LPL): Extracellular enzyme anchored by heparan sulfate proteoglycan chains to the capillary endothelium in muscle and adipose vascular beds; hydrolyzes core triacylglycerols of chylomicrons and VLDL into free fatty acids and monoacylglycerols.
- Transport Pathways:

- Exogenous Pathway (Dietary Fat Processing):
- Ingested fats are emulsified in the duodenum by bile salts and degraded into free fatty acids and 2-monoacylglycerols by pancreatic lipases.
- Breakdown products enter intestinal mucosal cells, where they are re-esterified into triacylglycerols.
- Triacylglycerols, cholesterol, cholesteryl esters, and phospholipids assemble around Apo B-48 to form nascent chylomicrons.
- Nascent chylomicrons are exocytosed into the lymphatic lacteals, pass into the bloodstream via the thoracic duct, and acquire Apo C-II and Apo E from circulating HDL to become mature chylomicrons.
- In capillary beds of muscle and adipose tissue, Apo C-II activates lipoprotein lipase, which hydrolyzes core triacylglycerols into free fatty acids that diffuse into tissues for energy generation () or storage.
- Depletion of the core lipids converts the particle into a chylomicron remnant enriched in cholesteryl esters. The remnant travels to the liver, where exposed Apo E binds remnant receptors, triggering receptor-mediated endocytosis and lysosomal digestion.
- Endogenous Pathway (Hepatic Lipid Transport):
- Excess carbohydrates and fatty acids in the liver are synthesized into triacylglycerols and packaged with cholesterol, cholesteryl esters, and Apo B-100 into nascent VLDL.
- VLDL acquires Apo C-II and Apo E in the circulation and encounters LPL in peripheral capillaries, releasing free fatty acids to muscle and adipose tissue.
- As triacylglycerols are progressively extracted, VLDL is converted into intermediate-density lipoprotein (.
- Approximately half of the IDL particles are recognized via Apo E and cleared directly by hepatic LDL receptors. The remaining IDL particles are further hydrolyzed by hepatic lipase, losing Apo E to become low-density lipoprotein (, which retains only Apo B-100).
- Circulating LDL delivers cholesteryl esters to peripheral extrahepatic cells and the liver via receptor-mediated endocytosis.
LDL Receptor-Mediated Endocytosis and Cellular Uptake
- Receptor Architecture:
- The LDL receptor is a single-pass transmembrane glycoprotein that localizes to specialized clathrin-coated pits on the cell surface.
- It contains an extracellular amino-terminal domain composed of cysteine-rich repeats that bind specifically to Apo B-100 on LDL particles, followed by an EGF precursor-like domain with a -propeller structure, an O-linked sugar region, a transmembrane segment, and a short cytosolic carboxy-terminal tail containing the NPXY internalization sequence.

- Stepwise Endocytic Cycle:
- LDL Binding: Apo B-100 of the circulating LDL particle binds with high affinity to the extracellular ligand-binding domain of the LDL receptor in an open, extended conformation.
- Internalization: The clathrin-coated pit invaginates and pinches off from the plasma membrane via dynamin to form an intracellular clathrin-coated vesicle.
- Vesicle Uncoating and Endosomal Fusion: The vesicle rapidly sheds its clathrin lattice and fuses with an uncoupling endosome (early endosome).
- pH-Dependent Conformation Change and Uncoupling: ATP-dependent proton pumps () acidify the lumen of the endosome to . This acidic environment protonates key histidine residues, causing the LDL receptor to shift into a closed, compact conformation. In this state, its -propeller domain binds intramolecularly to its own ligand-binding repeats, displacing the LDL particle.
- Receptor Recycling: The unoccupied receptor is segregated into tubular extensions of the endosome that bud off to form recycling vesicles, returning the intact receptor to the plasma membrane (a single receptor completes an endocytic cycle every , surviving up to ).
- Lysosomal Hydrolysis: The detached LDL remains in the endosomal lumen, which matures and fuses with a lysosome. Lysosomal proteases digest Apo B-100 into individual amino acids, and lysosomal acid lipases hydrolyze cholesteryl esters into free unesterified cholesterol and free fatty acids (such as oleate).

- Downstream Cellular Effects of Internalized Cholesterol:
- The unesterified cholesterol released into the cytoplasm exerts three coordinated regulatory effects:
- Downregulates de novo cholesterol biosynthesis by inhibiting HMGR transcription and accelerating HMGR protein degradation.
- Suppresses the transcription of the gene encoding the LDL receptor, preventing further uptake of external cholesterol.
- Activates acyl-CoA:cholesterol acyltransferase (), an enzyme that re-esterifies excess free cholesterol into cholesteryl esters for safe storage in cytosolic lipid droplets.
Familial Hypercholesterolemia and Atherosclerosis
Molecular Etiology of Familial Hypercholesterolemia (FH):
- Familial hypercholesterolemia is an inherited metabolic disease caused by autosomal dominant mutations in the gene encoding the LDL receptor (located on chromosome 19).
- Classes of Genetic Mutations:
- Receptor-negative mutations (no receptor synthesized).
- Transport-deficient mutations (receptor synthesized but blocked in ER-to-Golgi trafficking).
- Binding-defective mutations (receptor arrives at cell surface but cannot bind Apo B-100).
- Internalization-defective mutations (receptor binds LDL but cannot cluster into clathrin-coated pits due to mutations in the cytosolic NPXY motif).
- Recycling-defective mutations (receptor fails to transition from the closed to open state in the endosome, targeting the receptor to the lysosome for destruction rather than recycling).
Atherosclerotic Plaque Formation:
- Without functional LDL receptors, clearance of LDL from the circulation is impaired, causing plasma LDL-cholesterol concentrations to rise dramatically (often reaching normal levels in heterozygotes and in homozygotes).
- Excess circulating LDL particles enter the arterial subendothelial space (the tunica intima), where they become oxidized by reactive oxygen species, generating oxidized LDL (.
- oxLDL triggers an inflammatory response in overlying endothelial cells, stimulating the display of adhesion molecules that recruit circulating monocytes into the subendothelium.
- Monocytes differentiate into macrophages and upregulate scavenger receptors (e.g., SR-A and CD36). Unlike the tightly regulated LDL receptor, scavenger receptors ingest oxLDL without feedback inhibition.
- Macrophages become engorged with cholesteryl esters and convert into foam cells.
- Aggregated foam cells undergo apoptosis and necrosis, releasing a core of free cholesterol, necrotic debris, and inflammatory cytokines. This lesion stimulates smooth muscle cell migration, proliferation, and collagen deposition, forming a fibrous cap over the lipid core (atheromatous plaque).
- Progressive plaque expansion narrows the arterial lumen, restricting blood flow and predisposing the plaque to rupture. Plaque rupture triggers thrombosis, resulting in acute myocardial infarction or ischemic stroke.

Clinical Strategies for Hypercholesterolemia Management
Therapeutic management of elevated blood cholesterol focuses on depleting intracellular hepatic cholesterol pools, which upregulates hepatic LDL receptor expression and accelerates the clearance of atherogenic LDL particles from the bloodstream.
Two-Pronged Therapeutic Strategy:
- Inhibition of Bile Salt Reabsorption (Bile Acid Sequestrants):
- Under normal conditions, of secreted bile salts are reabsorbed in the terminal ileum and returned to the liver via the enterohepatic circulation.
- Patients ingest non-absorbable, positively charged, high-molecular-weight ion-exchange resins (such as cholestyramine or colestipol).
- These resins bind electrostatically to the negatively charged carboxylate and sulfonate groups of bile salts within the intestinal lumen, preventing their reabsorption and promoting their excretion in the feces.
- To compensate for this loss, hepatocytes must divert intracellular cholesterol toward the de novo synthesis of replacement bile salts via the pathway.
- Inhibition of De Novo Synthesis (Statins):
- To prevent hepatocytes from compensating for bile acid loss by upregulating de novo cholesterol biosynthesis, patients receive a class of pharmaceuticals called statins (e.g., lovastatin, simvastatin, atorvastatin, rosuvastatin).
- Mechanism of Action: Statins feature an active structural pharmacophore—an open-ring unit (or an inactive lactone prodrug that is hydrolyzed in vivo to the form) that structurally mimics both HMG-CoA and the mevaldyl-CoA tetrahedral transition state.
- Statins act as potent, reversible competitive inhibitors of HMG-CoA reductase, binding to its catalytic active site with nanomolar affinity (, compared to the substrate ).


- Synergistic Outcome of Combined Therapy:
- Blocking bile acid reabsorption depletes the hepatic cholesterol pool, while statins block endogenous replacement synthesis.
- The resulting fall in intracellular cholesterol triggers the SREBP/SCAP pathway in hepatocytes.
- This activates SREBP cleavage, causing the transcription factor to enter the nucleus and stimulate expression of the LDL receptor gene.
- With increased numbers of functional LDL receptors on the hepatocyte surface, clearance of circulating LDL from the bloodstream increases, lowering total plasma cholesterol and reducing cardiovascular risk.
Questions & Discussion
- Question: Which kinetic variables are affected by the presence of a competitive inhibitor, and how are they altered on a molecular level?
- Response: A competitive inhibitor structurally resembles the normal substrate and competes for binding at the enzyme active site. Because the inhibitor and substrate are mutually exclusive, adding excess substrate can overcome the inhibitor. Consequently:
- Michaelis Constant (): The apparent () increases in the presence of a competitive inhibitor by a factor of , reflecting a lower apparent affinity of the enzyme for its substrate.
- Maximum Velocity (): The remains unchanged because at high substrate concentrations (), the substrate outcompetes the inhibitor, allowing the enzyme to achieve its original maximum catalytic velocity.